Healthcare
Roche Commits Up to $2 Billion to Atavistik’s Small-Molecule Discovery Platform
Roche’s agreement with Atavistik Bio targets cardiovascular, kidney and metabolic disease, extending Big Pharma’s push to source novel drug platforms…
Roche’s agreement with Atavistik Bio targets cardiovascular, kidney and metabolic disease, extending Big Pharma’s push to source novel drug platforms…
Novo Nordisk has licensed Nanexa’s PharmaShell platform in a deal worth up to €1.165 billion, targeting monthly or potentially quarterly…
Eli Lilly and China’s InnoCare have formed a research and licensing partnership covering up to five targets, adding to a…
RPG Life Sciences is evaluating larger API acquisitions after spending Rs 215 crore on two deals, with more than Rs…
Read next